Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares have skyrocketed 136% during the trading session on Tuesday. The positive performance of the company’s share has shown the positive sentiments of the investors as the firm has confirmed that two of its newly created mRNA molecules are proven useful at destroying cancer cells grown in culture.
The cytotoxicity tests were carried out on a variety of cancer cells, including MCF-7/MDR multidrug-resistant breast cancer cells, OVCAR-3 ovarian adenocarcinoma cells, and pancreatic cancer cells (SUIT-2). These mRNA molecules have minimal or no harmful effects in non-transformed (normal) human cells (HMEC cells), according to toxicity studies.
Dr. Steve Slilaty, CEO of Sunshine Biopharma, remarked, "We are excited by these discoveries in association with our continuing mRNA-as-therapeutic-agents study." He continued, "The prospective use of mRNA to treat cancer paves the way to several options for patients, including ease, lower toxicity, and improved efficacy."
Furthermore, the mRNA vaccination technique can easily adapt these novel mRNA molecules for delivery to patients. In light of these findings, the Company plans to file a patent application soon. In addition, Sunshine Biopharma is developing a therapy for COVID-19 and has finished the synthesis of four candidate PLpro inhibitors, from which a lead drug, SBFM-PL4, has been found.